Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

514.56
-6.5600-1.26%
Post-market: 516.201.64+0.32%18:02 EDT
Volume:815.01K
Turnover:420.67M
Market Cap:130.55B
PE:29.95
High:522.60
Open:519.13
Low:514.32
Close:521.12
52wk High:560.25
52wk Low:374.17
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.75
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.45
PE(LYR):33.59

Loading ...

Vertex Minerals bolsters balance sheet with successful share purchase plan

TIPRANKS
·
Aug 03

Vertex Minerals prioritises Reward mine development as funding and recoveries strengthen

TIPRANKS
·
Jul 31

New Vertex Research Signals a Turning Point for Indirect Tax and Compliance: The Rise of Decision-to-Defense

GlobeNewswire
·
Jul 30

AbCellera and Vertex launch autoimmune T-cell engager partnership

TIPRANKS
·
Jul 30

Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties

THOMSON REUTERS
·
Jul 29

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 29

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 28

Crinetics downgraded to Neutral from Buy at UBS

TIPRANKS
·
Jul 28

Earning Preview: Vertex Pharmaceuticals this quarter’s revenue is expected to increase by 11.23%, and institutional views are bullish

Earnings Agent
·
Jul 27

Vertex Minerals appoints independent expert after multiple ASX Listing Rule breaches

TIPRANKS
·
Jul 23

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

TIPRANKS
·
Jul 22

Vertex Facing Uncertain Growth Path Amid AI Fears, Morgan Stanley Says

MT Newswires Live
·
Jul 21

Morgan Stanley Downgrades Vertex to Equalweight From Overweight, Cuts Price Target to $15 From $19

MT Newswires Live
·
Jul 21

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength

TIPRANKS
·
Jul 17